-
Recruiting
NCT NCT07163650
Evaluating Anti-Obesity Medications 6 Months After Metabolic Surgery
Not yet reported
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
60 participants
Est. completion 2027-02-28
1 site
Stand-alone
Other conditions: Obesity, Weight Loss, Metabolic Surgery
View official trial listing →
-
Recruiting
NCT NCT07693426
Phase Ib Study of Efsubaglutide Alfa Injection in Obese Adolescents
Not yet reported
Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
36 participants
Est. completion 2027-08-31
5 sites
Stand-alone
Other conditions: Adolescence Obesity
View official trial listing →
-
Completed
NCT NCT06732960
A Study of the Efficacy and Safety of Efsubaglutide Alfa in Overweight or Obesity Patients
Not yet reported
Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
50 participants
Est. completion 2024-11-18
3 sites
Stand-alone
Other conditions: Overweight or Obesity
View official trial listing →
-
Completed
NCT NCT06849843
A Study of 3mg Once Every Two Weeks Administration of Efsubaglutide Alfa Injection in Type 2 Diabetes Patients.
Not yet reported
Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
59 participants
Est. completion 2025-05-29
10 sites
Stand-alone
Type 2 diabetes
View official trial listing →
-
Not yet recruiting
NCT NCT06900075
Efficacy and Safety of Efsubaglutide Alfa Injection 3 Mg Q2W in T2D Patients
Not yet reported
Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
88 participants
Est. completion 2026-03-31
Stand-alone
Type 2 diabetes
View official trial listing →
-
Active, not recruiting
NCT NCT06921486
The Efficacy and Safety of Efsubaglutide Alfa Injection in Overweight and Obese Subjects (ENLIGHT)
Not yet reported, Not yet reported
Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
1003 participants
Est. completion 2026-12-31
41 sites
Stand-alone
Other conditions: Obesity and Overweight
View official trial listing →
-
Completed
NCT NCT07114419
The Efficacy and Safety of Efsubaglutide Alfa in Overweight/Obesity(SPARKLE)
Not yet reported
Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
200 participants
Est. completion 2026-07-06
5 sites
Stand-alone
Other conditions: Obesity and Overweight
View official trial listing →
-
Not yet recruiting
NCT NCT07518121
A Bridging Study of Efsubaglutide Alfa in Healthy Adults in Brazil
Not yet reported
Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
48 participants
Est. completion 2026-10-31
1 site
Stand-alone
Other conditions: Diabete Type 2
View official trial listing →